Cited by 303Epigenetics and DNA MethylationChromatin Remodeling and CancerCancer Cells and Metastasis

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Poised epigenetic states and acquired drug resistance in cancer

Brown, Robert, Curry, Edward, Magnani, Luca, Wilhelm-Benartzi, Charlotte S., Borley, Jane·2014·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Epigenetic events, which are somatically inherited through cell division, are potential drivers of acquired drug resistance in cancer. The high rate of epigenetic change in tumours generates diversity in gene expression patterns that can rapidly evolve through drug selection during treatment, leading to the development of acquired resistance. This will potentially confound stratified chemotherapy decisions that are solely based on mutation biomarkers. Poised epigenetic states in tumour cells may drive multistep epigenetic fixation of gene expression during the acquisition of drug resistance, which has implications for clinical strategies to prevent the emergence of drug resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc3819

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,526
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9
Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014) · Nature · doi:10.1038/nature13011 · Cited by 1,822
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Chromatin signatures of pluripotent cell lines
Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jørgensen, H. F., John, R. M., Gouti, M., Casanova, M., Warnes, G., Merkenschlager, M., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1403 · Cited by 1,357
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacıoğlu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,282
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., Brooks, M. W., Reinhardt, F., Su, Y., Polyák, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102454108 · Cited by 1,170
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1123 · Cited by 1,165
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136
A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Unravelling cancer stem cell potential
Beck, B., & Blanpain, C. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3597 · Cited by 915
Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity
Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G. W., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 903
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A., & Downing, J. R. (2008) · Science · doi:10.1126/science.1164266 · Cited by 806
Genetic variegation of clonal architecture and propagating cells in leukaemia
Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S., Kempski, H. M., Moorman, A. V., Titley, I., Swansbury, J. G., et al. (2010) · Nature · doi:10.1038/nature09650 · Cited by 803
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Scott, M. P., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 794
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Li, S., Shen, D., Shao, J., Crowder, R. J., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 637
Oxidative Damage Targets Complexes Containing DNA Methyltransferases, SIRT1, and Polycomb Members to Promoter CpG Islands
O’Hagan, H. M., Wang, W., Sen, S., Shields, C. E. D., Lee, S. S., Zhang, Y. W., Clements, E. G., Cai, Y., Neste, L. V., Easwaran, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.012 · Cited by 593
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Pujade-Lauraine, É., Wagner, U. A. G., Aavall-Lundqvist, E., Gebski, V., Heywood, M. S., Vasey, P. A., Volgger, B., Vergote, I. B., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 573
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H. X., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 557
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A. J., Boon, U., Sol, W., van Deemter, L., Zander, S. A. L., Drost, R., Wientjens, E., Ji, J. J., Aly, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 532
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
Self-citation
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Konze, K. D., Ma, A., Li, F., Baršytė-Lovejoy, D., Parton, T., MacNevin, C. J., Liu, F., Gao, C., Huang, X., Kuznetsova, E., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400133j · Cited by 463
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
Verma, S. K., Tian, X., LaFrance, L. V., Duquenne, C., Suarez, D., Newlander, K. A., Romeril, S. P., Burgess, J. L., Grant, S. W., Brackley, J. A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003346 · Cited by 390
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 387
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996) · PubMed · Cited by 386
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J., Lohr, J. G., Cotton, M. J., Gillespie, S. M., Fernandez, D. E., Ku, M., Wang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2913 · Cited by 376
Locus-specific editing of histone modifications at endogenous enhancers
Mendenhall, E. M., Williamson, K. E., Reyon, D., Zou, J., Ram, O., Joung, J. K., & Bernstein, B. (2013) · Nature Biotechnology · doi:10.1038/nbt.2701 · Cited by 371
Investigating stem cells in human colon by using methylation patterns
Yatabe, Y., Tavaré, S., & Shibata, D. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191225998 · Cited by 368
A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
Strathdee, G. R., Mackean, M., Illand, M., & Brown, R. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350
Self-citation
Strategies for the management of adverse events associated with mTOR inhibitors
Kaplan, B. E., Qazi, Y. A., & Wellen, J. R. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2014.03.002 · Cited by 327
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 304
A DNA hypermethylation module for the stem/progenitor cell signature of cancerPreprint
Easwaran, H., Johnstone, S. E., Neste, L. V., Ohm, J. E., Mosbruger, T., Wang, Q., Aryee, M. J., Joyce, P., Ahuja, N., Weisenberger, D., et al. (2012) · Genome Research · doi:10.1101/gr.131169.111 · Cited by 295
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
Zeller, C., Dai, W., Steele, N. L., Siddiq, A., Walley, A. J., Wilhelm-Benartzi, C. S., Rizzo, S., van der Zee, A. G. J., Plumb, J. A., & Brown, R. E. (2012) · Oncogene · doi:10.1038/onc.2011.611 · Cited by 286
Self-citation
Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.
Thomas, A., Rouby, S. E., Reed, J. C., Krajewski, S., Silber, R.-E., Potmĕsil, M., & Newcomb, E. (1996) · PubMed · Cited by 265
The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., & Brown, R. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262
Self-citation
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2795 · Cited by 262
Epigenetics as a mechanism driving polygenic clinical drug resistance
Glasspool, R. M., Teodoridis, J. M., & Brown, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603024 · Cited by 236
Self-citation
Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors
Appleton, K., MacKay, H. J., Judson, I. R., Plumb, J. A., McCormick, C., Strathdee, G. R., Lee, C., Barrett, S., Reade, S., Jadayel, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8688 · Cited by 228
Self-citation
Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
Rizzo, S., Hersey, J. M., Mellor, P., Dai, W., Santos‐Silva, A., Liber, D., Luk, L., Titley, I., Carden, C. P., Box, G., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0788 · Cited by 203
Self-citation
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
Magnani, L., Stoeck, A., Zhang, X., Lánczky, A., Mirabella, A., Wang, T., Győrffy, B., & Lupien, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219992110 · Cited by 187
Self-citation
Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer
Fu, S., Hu, W., Iyer, R. B., Kavanagh, J. J., Coleman, R. L., Levenback, C. F., Sood, A. K., Wolf, J. K., Gershenson, D. M., Markman, M. M., et al. (2010) · Cancer · doi:10.1002/cncr.25701 · Cited by 183
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5
Senisterra, G. A., Wu, H. Y., Allali‐Hassani, A., Wasney, G. A., Baršytė-Lovejoy, D., Dombrovski, L., Dong, A., Nguyen, K. T., Smil, D. V., Bolshan, Y., et al. (2012) · Biochemical Journal · doi:10.1042/bj20121280 · Cited by 165
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Garapaty, S., Nasveschuk, C. G., Gagnon, A., Chan, E. Y., Sandy, P., Busby, J., Balasubramanian, S., Campbell, R., Zhao, F., Bergeron, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.013 · Cited by 159
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts
Kitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0560 · Cited by 151
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
Chen, Q., van der Sluis, P. C., Boulware, D. C., Hazlehurst, L., & Dalton, W. S. (2005) · Blood · doi:10.1182/blood-2004-11-4286 · Cited by 143
O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Brandes, A. A., Franceschi, E., Tosoni, A., Bartolini, S., Bacci, A., Agati, R., Ghimenton, C., Turazzi, S., Talacchi, A., Škrap, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop050 · Cited by 143
Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts
Topp, M. D., Hartley, L., Cook, M., Heong, V. Y. M., Boehm, E., McShane, L., Pyman, J. M., McNally, O., Ananda, S. S., Harrell, M., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.008 · Cited by 141
Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells
Li, H., Cai, Q. K., Godwin, A. K., & Zhang, R. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0398 · Cited by 133
Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers
Chang, X., Monitto, C. L., Demokan, S., Kim, M. S., Chang, S. S., Zhong, X., Califano, J. A., & Sidransky, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3427 · Cited by 129
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
Glasspool, R. M., Brown, R. E., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.116 · Cited by 125
Self-citation
DNA repair in resistance to alkylating anticancer drugs
Kaina, B., & Christmann, M. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40354 · Cited by 117
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma
Christmann, M., Nagel, G., Horn, S., Krahn, U., Wiewrodt, D., Sommer, C., & Kaina, B. (2010) · International Journal of Cancer · doi:10.1002/ijc.25229 · Cited by 117
The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer
Zhuang, J. J., Jones, A., Lee, S., Ng, E., Fiegl, H., Zikán, M., Cibula, D., Sargent, A., Salvesen, H. B., Jacobs, I. J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002517 · Cited by 117
Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells
Papouli, E., Ćejka, P., & Jiricny, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0513 · Cited by 116
Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer
Zhang, Y., Zheng, Y., Wang, J., Lu, X., Wang, Z., Chen, L., Guan, X., & Tong, J. (2014) · Epigenetics · doi:10.4161/epi.28601 · Cited by 112
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
Dizon, D. S., Blessing, J. A., Penson, R. T., Drake, R. D., Walker, J. L., Johnston, C. M., DiSilvestro, P., & Fader, A. N. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.02.019 · Cited by 102
Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
Parkinson, J., Wheeler, H., Clarkson, A., McKenzie, C. A., Biggs, M. T., Little, N., Cook, R., Messina, M., Robinson, B. G., & McDonald, K. L. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9486-0 · Cited by 91
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells
Chapman‐Rothe, N., Curry, E. W., Zeller, C., Liber, D., Stronach, E. A., Gabra, H., Ghaem‐Maghami, S., & Brown, R. E. (2012) · Oncogene · doi:10.1038/onc.2012.477 · Cited by 90
Self-citation
Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer
Jansen, M. P. H. M., Knijnenburg, T., Reijm, E. A., Simón, I., Kerkhoven, R. M., Droog, M., Velds, A., Laere, S. V., Dirix, L. Y., Alexi, X., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0704 · Cited by 90
Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer
Dizon, D. S., Damstrup, L., Finkler, N. J., Lassen, U., Celano, P., Glasspool, R. M., Crowley, E. M., Lichenstein, H. S., Knoblach, P., & Penson, R. T. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31825736fd · Cited by 86
A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
Garrido‐Laguna, I., McGregor, K., Wade, M. L., Weis, J. R., Gilcrease, W., Burr, L., Soldi, R., Jakubowski, L., Davidson, C., Morrell, G., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9947-6 · Cited by 69
The evolution of the unstable cancer genome
Burrell, R. A., & Swanton, C. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.011 · Cited by 66
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
Falchook, G. S., Fu, S., Naing, A., Hong, D. S., Hu, W., Moulder, S. L., Wheler, J. J., Sood, A. K., Bustinza-Linares, E., Parkhurst, K. L., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0003-3 · Cited by 65
Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
Fan, H., Lu, X.-C., Wang, X., Liu, Y., Guo, B., Zhang, Y., Zhang, W., Nie, J., Feng, K., Chen, M., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/371087 · Cited by 64
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer
Sonpavde, G., Aparicio, A. M., Zhan, F., North, B., Delaune, R., Garbo, L. E., Rousey, S. R., Weinstein, R. E., Xiao, L., Boehm, K. A., et al. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.09.015 · Cited by 62
The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas
Park, C., Kim, J., Kim, J. Y., Song, S. W., Kim, J. W., Choi, S. H., Kim, T. M., Lee, S., Kim, I. H., & Park, S. (2012) · Translational Oncology · doi:10.1593/tlo.12253 · Cited by 59
Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer
Zeller, C., & Brown, R. E. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010375759 · Cited by 56
Self-citation
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma
Jung (2010) · Oncology Reports · doi:10.3892/or_00000760 · Cited by 52
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
Bauer, S., Hilger, R. A., Mühlenberg, T., Grabellus, F., Nagarajah, J., Hoiczyk, M., Reichardt, A., Ahrens, M., Reichardt, P., Grünewald, S., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.826 · Cited by 50
A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.
Watanabe, Y., Ueda, H., Etoh, T., Koike, E., Fujinami, N., Mitsuhashi, A., & Hoshiai, H. (2007) · PubMed · Cited by 49
Current Limitations And Future Opportunities For Epigenetic Therapies
Cherblanc, F., Chapman‐Rothe, N., Brown, R. E., & Fuchter, M. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.7 · Cited by 44
Self-citation
In situ hybridization analysis of acquisition and loss of the human multidrug-resistance gene.
Shen, D. W., PASTAN, I., & Gottesman, M. M. (1988) · PubMed · Cited by 29
Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance
Monsma, D. J., Cherba, D., Richardson, P. J., Vance, S. M., Rangarajan, S. V., Dylewski, D., Eugster, E., Scott, S. B., Beuschel, N. L., Davidson, P. J., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25039 · Cited by 24
Approaches to Target the Genome and Its Epigenome in Cancer
Chapman‐Rothe, N., & Brown, R. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.105 · Cited by 9
Self-citation

Flagged first, then by citations

Sorted by citations

The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,957
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00308-y · Cited by 993
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kölch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 823
Tumorigenesis: it takes a village
Tabassum, D. P., & Polyák, K. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3971 · Cited by 558
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 392

See all 303

Authors: Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J.
Affiliations: Hammersmith Hospital (GB)
Corresponding author: Brown, Robert
ORCID: Brown, Robert
Curry, Edward
Magnani, Luca
Wilhelm-Benartzi, Charlotte S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-09-25
Volume: 14
Issue: 11
Pages: 747-753
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3819
OpenAlex: W2095124748
Cited by: 301
References: 96
Citations by year: 2026: 4 · 2025: 16 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 41 · 2020: 37 · 2019: 34 · 2018: 27 · 2017: 23 · 2016: 30 · 2015: 18 · 2014: 1
FWCI: 2.29
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders: Cancer Research UK (13086, A13086, 15954)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: epigenetic heterogeneity, acquired drug resistance, cancer, epigenetic targeting, chemoresistance, gene expression evolution
MeSH terms: Animals, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Poised epigenetic states and acquired drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks